USA flag logo/image

An Official Website of the United States Government

Organocatalysis for the Treatment of Sickle Cell Disease.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43HL106862
Solicitation Year:
2011
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA10-050
Small Business Information
NANOMETICS, LLC
50 E 8TH ST, STE 6N NEW YORK, NY 10003-6502
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Organocatalysis for the Treatment of Sickle Cell Disease.
Agency: HHS
Contract: 1R43HL106862-01
Award Amount: $243,469.00
 

Abstract:

DESCRIPTION (provided by applicant): One potential therapeutic approach to treat sickle cell disease (SCD) involves the administration of aryl aldehyde-containing small molecules that form Schiff base adducts with hemoglobin (HbS) and prevent sickling. Theutility of this approach is inherently limited as the kinetics of Schiff base formation between an aryl aldehyde and 1-amino group of HbS is kinetically slow under physiological conditions. Our approach utilizes benign organic catalysts to create a highlyreactive therapeutic (AIC) in situ that reacts with HbS at enhanced rates. In preliminary studies, the addition of just 1 mM catalyst dramatically increased Schiff base adduct formation with Hb, as measured by the changes in oxygen affinity. We hypothesize that this strategy will be clinically useful in reducing the therapeutic doses required for efficacy, thus attenuating the likelihood of adverse effects The two Specific Aims of the proposed project are: (I) determination of the optimum levels of aldehyde and catalyst required to achieve different levels of adduct formation with free Hb in solution and in SS red blood cells, and (II) establish the effect of catalyst on the Ex vivo red blood cell sickling and morphology of SS cells by microscopy, and confirm the influence of catalyst on the degree of Schiff base adduct formation using cation exchange chromatography. Phase II efforts include in vivo evaluations of catalyst influence on efficacy in a murine sickle cell model under hypoxic conditions, pharmokinetic studies including bioavailability, and the study of any adverse effects. We plan to commercialize the AIC, formed by reaction between a benign organic catalyst and aromatic aldehyde, as a novel therapeutic for the treatment of SCD. After completion of Phase II efforts, we will partner with a multinational pharmaceutical company to develop the therapeutics through clinical trials. PUBLIC HEALTH RELEVANCE: Sickle cell disease (SCD) is a genetic disorder that inflicts over 75,000 Americans and 13million people worldwide. This project seeks to advance the use of organic catalysts to provide for improved therapeutics that treat sickle cell disease at lower clinical doses.

Principal Investigator:

Steven Isaacman
646-267-5720
steve@nanometicslab.com

Business Contact:

Steven Isaacman
646-267-5720
steve@nanometicslab.com
Small Business Information at Submission:

NANOMETICS, LLC
50 E 8TH ST, STE 6N NEW YORK, NY 10003-6502

EIN/Tax ID: 126024039
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No